Home Tools
Log in
Cart

Ephrin Receptor

Eph receptors (Ephs, after erythropoietin-producing human hepatocellular receptors) are a group of receptors that are activated in response to binding with Eph receptor-interacting proteins (Ephrins). Ephs form the largest known subfamily of receptor tyrosine kinases (RTKs). Both Eph receptors and their corresponding ephrin ligands are membrane-bound proteins that require direct cell-cell interactions for Eph receptor activation. Eph/ephrin signaling has been implicated in the regulation of a host of processes critical to embryonic development including axon guidance, formation of tissue boundaries, cell migration, and segmentation. Additionally, Eph/ephrin signaling has recently been identified to play a critical role in the maintenance of several processes during adulthood including long-term potentiation, angiogenesis, and stem cell differentiation and cancer.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T80896 UniPR1449 98%
UniPR1449
UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].
T80897 UniPR1447 1809170-68-0 98%
UniPR1447
UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].
T1448L Dasatinib monohydrate 863127-77-9 99.89%
Dasatinib monohydrate
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib mon...
T38511 AWL-II-38.3 1135205-94-5 99.87%
AWL-II-38.3
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show ...
T67736 ALW-II-49-7 1135219-23-6 99.84%
ALW-II-49-7
ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.
TP1895L1 KYL acetate(676657-00-4 free base) 99.75%
KYL acetate(676657-00-4 free base)
KYL acetate is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic da...
T4349 Sitravatinib 1123837-84-2 99.74%
Sitravatinib
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
T19487 NVP-BHG712 isomer 2245892-85-5 99.65%
NVP-BHG712 isomer
NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.
T5451 Eph inhibitor 2 861249-59-4 99.48%
Eph inhibitor 2
Eph inhibitor 2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
T3476 JI-101 900573-88-8 99.41%
JI-101
JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor rec...
T73368 UniPR505 2938227-14-4 99.23%
UniPR505
UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.
TP1561 123C4 2034159-30-1 98.94%
123C4
123C4 is a novel, potent, and selective agonist of the tyrosine kinase EphA4 receptor.
T2456 Tivozanib 475108-18-0 98.23%
Tivozanib
Tivozanib (KRN951) is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and anti...
T4344 ALW-II-41-27 1186206-79-0 98.17%
ALW-II-41-27
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
T9650 AZ12672857 945396-55-4 98.05%
AZ12672857
AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphoryl...
T5452 Ehp-inhibitor-2 861249-77-6 98.02%
Ehp-inhibitor-2
Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
T6348 NVP-BHG712 940310-85-0 97.96%
NVP-BHG712
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
TQ0166 Tesevatinib 781613-23-8 97.89%
Tesevatinib
Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4)....
UniPR1449
T80896
UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].
UniPR1447
T80897
UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].
Dasatinib monohydrate
T1448L
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib mon...
AWL-II-38.3
T38511
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show ...
ALW-II-49-7
T67736
ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.
KYL acetate(676657-00-4 free base)
TP1895L1
KYL acetate is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic da...
Sitravatinib
T4349
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
NVP-BHG712 isomer
T19487
NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.
Eph inhibitor 2
T5451
Eph inhibitor 2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
JI-101
T3476
JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor rec...
UniPR505
T73368
UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.
123C4
TP1561
123C4 is a novel, potent, and selective agonist of the tyrosine kinase EphA4 receptor.
Tivozanib
T2456
Tivozanib (KRN951) is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and anti...
ALW-II-41-27
T4344
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
AZ12672857
T9650
AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphoryl...
Ehp-inhibitor-2
T5452
Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
NVP-BHG712
T6348
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
Tesevatinib
TQ0166
Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4)....
TargetMol